WO2005070393A2 - Directly compressible pharmaceutical composition of the rapamycin ester cci-779 - Google Patents
Directly compressible pharmaceutical composition of the rapamycin ester cci-779 Download PDFInfo
- Publication number
- WO2005070393A2 WO2005070393A2 PCT/US2004/042178 US2004042178W WO2005070393A2 WO 2005070393 A2 WO2005070393 A2 WO 2005070393A2 US 2004042178 W US2004042178 W US 2004042178W WO 2005070393 A2 WO2005070393 A2 WO 2005070393A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cci
- micronized
- dosing unit
- oral
- unit according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Definitions
- Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) is an anticancer agent and is characterized by the following structure.
- CCI-779 CCI-779 exhibits cytostatic, as opposed to cytotoxic properties, and may delay the progression of tumors or tumor recurrence.
- the mechanism of action of CCI-779 that results in the Gl to S phase block is novel for an anticancer drug.
- CCI-779 has been shown to inhibit the growth of a number of histologically diverse tumor cells.
- Central nervous system (CNS) cancer, leukemia (T-cell), breast cancer, prostate cancer, and melanoma lines were among the most sensitive to CCI-779.
- One obstacle towards the formulation of CCI-779 is its poor aqueous dissolution and low oral bio availability. Additionally, CCI-779 exhibits aqueous instability and has shown its potential to undergo oxidation.
- a CCI-779 formulation was developed that employed a wet granulation manufacturing process. US Published Patent Application, Publication No. US- 2004- 0077677- A 1.
- the present invention provides a convenient and effective method to deliver therapeutic levels of CCI-779 to the patient.
- the invention provides pharmaceutical compositions containing a stable and bioavailable form of micronized CCI-779, and optionally, an antioxidant or a chelating agent, or mixtures thereof, in an immediate release dosage form for oral administration.
- the composition is in the form of a tablet or in filled capsules.
- the invention provides micronized CCI-779, that can be readable formulated into an oral dosage unit, and is particularly well suited for a directly compressible unit.
- the inventors have found that tablets prepared by direct compression of micronized CCI-779 formulations of the invention exhibited rapid and complete drug release, as compared to nonmicronized CCI-779, even when the nonmicronized CCI-779 was formulated with surfactants. See, e.g., Example 4.
- the compositions of the invention provide fast drug release.
- CCI-779 is micronized under nitrogen and conventional micronizing techniques, for example with a Trost or jet mill, applied to non-micronized CCI-779.
- non-micronized CCI-779 The preparation of non-micronized CCI-779 is described in U.S. Patent 5,362,718, which is hereby incorporated by reference. A regioselective preparation of non-micronized CCI- 779 is described in US Patent 6,277,983, which is hereby incorporated by reference. However, the invention is not limited to the method by which the non-micronized CCI- 779 is produced. Micronized CCI-779 typically has a particle size of about 0.2 to about 30 microns, about 0.5 to 25 microns, or about 0.5 to 20 microns, as described above.
- compositions of the invention contain micronized CCI-779 with a particle size range in which 10% are less than or equal to about 3 microns ( ⁇ ), 50% are about 10 ⁇ , and 90% are less than or equal to about 20 ⁇ as determined by Malvern method.
- the micronized CCI-779 has a particle size range of 10% are less than or equal to about 2 ⁇ , 50% are about 5 ⁇ , and 90% are less than or equal to about 16 ⁇ as determined by Malvern method.
- the micronized CCI-779 is present in the composition of the invention in an amount from 0.1 %> w/w to 50%> w/w, based on the weight of an uncoated composition of the invention.
- micronized CCI-779 is generally in the range, e.g., about 0.1 to about 50 mg, about 10 mg to about 30 mg, or about 0.5 to about 2 mg micronized CCI-779.
- the desired therapeutic regimen can be taken into consideration when formulating a composition of the invention.
- micronized CCI-779 can be in the range of 0.1% w/w to 10% w/w for an uncoated composition of the invention.
- micronized CCI-779 can be in the range of 5% w/w to 25% w/w based upon the weight of an uncoated unit dose.
- micronized CCI-779 can be in the range of 6%> w/w to 8% w/w,
- the composition of the present invention can contain pharmaceutically acceptable additives and/or excipients. Typically, these additives are biologically inert and useful for manufacture of a dosing unit.
- the compositions of the invention may contain one or more filler/binder, disintegrant, a dissolution enhancer (including, e.g., a surfactant), glidant, and lubricant.
- the compositions further contain one or more antioxidants, chelating agents, or pH modifiers.
- the antioxidant, chelating agent, and/or pH modifier may be micronized.
- Micronized additives and excipients are prepared using conventional techniques, as described.
- pharmaceutically acceptable binders, fillers, and disintegrants include sucrose, lactose, magnesium stearate, gum acacia, cholesterol, tragacanth, stearic acid, gelatin, casein, lecithin (phosphatides), carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, dextrates, dextrin, lactose, dextrose, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, polyoxyethylene alkyl ethers, polyethylene glycols, polyoxyethylene castor oil derivatives, polyoxyethylene ste
- the disintegrant is croscarmellose sodium.
- a composition of the invention contains a total of about 3%> w/w to 8%> w/w disintegrant, e.g., about 4%> to about 6% w/w.
- the binders and fillers are selected from the group consisting of polyvinylpyrrolidone (povidone), lactose (including anhydrous lactose), and microcrystalline cellulose, and mixtures thereof.
- a composition of the invention contains a total of about 75 % w/w to 88%> w/w binder/filler, or about 80%o w/w to 82%> w/w binder/filler, based on the weight of an uncoated composition.
- a composition of the invention may contain, in addition to the micronized CCI-779 and other components, about a low amount of povidone, e.g. about 5 to 7% w/w, and more desirably, about 6%> w/w, with the remainder of the filler in the uncoated composition being supplied by other components.
- a composition of the invention may contain a high amount of povidone, e.g., about 25 to 35% w/w, and more desirably, about 30 to 32 % w/w povidone, with the remainder of the filler in the uncoated composition being supplied by other components.
- a composition of the invention contains a combination of lactose, preferably anhydrous lactose, and macrocrystalline cellulose, optionally with povidone or another filler/binder.
- anhydrous lactose is generally present in an amount of about 30% w/w to about 60% w/w, and more desirably, about 30 % w/w, about 32%> w/w, about 50%> w/w, or about 55% w/w anliydrous lactose.
- microcrystalline cellulose is present in an amount of about 15% w/w to about 30%) w/w of the uncoated composition, and more desirably, about 16% w/w, about 23%o w/w, about 25% w/w, about 28%> w/w of the uncoated composition.
- Dissolution enhancers may be included in the micronized CCI-779 composition (based on uncoated weight) of the invention.
- one or more dissolution enhancers may optionally be present in the composition in an amount of from about 0.5 % w/w to about 10 % w/w, and preferably, from about 5%> w/w to about 8% w/w, about 5.5%, about 6%> w/w, or 6.5% w/w, based on the weight of an uncoated composition.
- dissolution enhancers include surfactants, chelating agents (e.g., EDTA), disintegrants, or combinations thereof.
- the surfactant is about 0.25 % w/w to about 10 % w/w of an uncoated composition, and preferably, about 5% w/w to about 6.5% w/w.
- the surfactant is selected from sodium lauryl sulfate (also known as sodium dodecyl sulfate).
- suitable surfactants are well known to those of skill in the art and can be selected including, without limitation, polysorbates including, e.g.
- polysorbate 80 polysorbate 80, Polaxamer 188TM surfactant, sodium lauryl sulfate (sodium dodecyl sulfate), salts of bile acids (taurocholate, glycocholate, cholate, deoxycholate, etc.) which may be combined with lecithin.
- ethoxylated vegetable oils such as Cremophor EL, vitamin E tocopherol propylene glycol succinate (Vitamin E TGPS), polyoxyethylene- polyoxypropylene block copolymers, and poloxamers.
- Acceptable antioxidants include, but are not limited to, citric acid, d,l- - tocopherol, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), monothioglycerol, ascorbic acid, propyl gallate, and mixtures thereof. It is expected that the total amount of antioxidants in the formulations of this invention will be in concentrations ranging from 0.001%> to 3%> w/w, and preferably, about 0.01 w/w to about 1%) w/w, and more preferably, about 0.02 % w/w to 0.1% w/w, based on the weight of an uncoated composition.
- the antioxidant is a combination of BHA and BHT, which may be in nonmicronized form or preferably, in micronized form.
- Chelating agents and other materials capable of binding metal ions such as ethylene diamine tetra acetic acid (EDTA) and its salts and hydrates (e.g., EDTA calcium disodium hydrous) are useful in the compositions of the invention.
- EDTA ethylene diamine tetra acetic acid
- a chelating agent is present in an amount less than 1 % w/w, e.g., about 0.001 % w/w to about 0.01 % w/w, based on the weight of an uncoated composition.
- the chelating agent is present in micronized form.
- Acceptable pH modifying agents include, but are not limited to citric acid and salts thereof (e.g., sodium citrate), dilute HC1, and other mild acids or bases capable of buffering a solution containing CCI-779 to a pH of 4 to 6. Where present in a composition of the invention, such pH modifiers are present in an amount up to about 1% w/w, e.g., about 0.001% w/w to about 0.1%> w/w, based on the weight of an uncoated composition. Optionally, the pH modifier, can be present in micronized form. Other suitable components include lubricants and/or glidants.
- the lubricant and the glidants can each be present in the composition of the invention in an amount of 0.01 wt% to about 1 wt%, about 0.1 wt% to about 2 wt%o, or about 0.2 to about 0.5%), of an uncoated composition. In some embodiments, the lubricant and glidants are present in the composition in amounts of less than 1 wt%> of an uncoated composition.
- An example of a suitable lubricant is magnesium stearate and an example of a suitable glidants is silicone dioxide.
- Other suitable inert components of the formulation will be readily apparent to one of skill in the art.
- the compositions of the invention are formed into a suitable dosing unit for delivery to a patient.
- Suitable dosing units include oral dosing units, such as a directly compressible tablet, a capsule, a powder and a suspension.
- the compositions of the invention can also be formulated for delivery by other suitable routes. These dosing units are readily prepared using the methods described herein and those known to those of skill in the art.
- a composition of the invention is prepared by dry mixing micronized CCI-779 with the other additives in a suitable mixer. The powder mix is then directly compressed into unit dose tablets.
- an example of a suitable micronized CCI-779 formulation includes a low amount of povidone. The following weight percentages are based upon an uncoated composition of the invention.
- a suitable micronized CCI-779 composition contains a high amount of povidone, with weight percentages based upon an uncoated composition of the invention: Micronized CCI-779 6 % w/w; Sodium Lauryl Sulfate 6%> w/w; Povidone 31 % w/w; Lactose Anliydrous 34% w/w; Microcrystalline Cellulose 16% w/w; Croscarmellose Sodium 6% w/w ; Glidant 0.25% w/w; and Magnesium Stearate 0.5% w/w.
- micronized CCI-779 dosing unit with weight percentages based on total uncoated composition, is: Micronized CCI-779 6% w/w; Butylated Hydroxyanisol 0.022% w/w; Butylated Hydroxytoluene 0.05 % w/w; EDTA 0.011% w/w; Citric acid 0.08% w/w Poloxamer 188 6% w/w Lactose Anliydrous 55% w/w Microcrystalline Cellulose 28 w/w Croscarmellose Sodium 4% w/w Glidant 0.25% w/w; and Magnesium Stearate 0.5% w/w.
- a suitable dosing unit with weight percentages based on total uncoated composition, is: CCI-779 (Micronized) 6% w/w; Butylated Hydroxyanisole (Micronized) 0.022%o w/w; Butylated Hydroxytoluene (Micronized) 0.05% w/w; EDTA Calcium Disodium, Hydrous (Micronized) 0.011% w/w; Citric Acid Anhydrous (Micronized) 1 % w/w; Sodium Lauryl Sulfate 6%> w/w; Povidone K-25 65% w/w; Microcrystalline Cellulose 23% w/w; Anhydrous Lactose 50% w/w; Croscarmellose Sodium 6 % w/w; Colloidal Silicone Dioxide 0.25% w/w; and Magnesium Stearate 0.50% w/w.
- the tablets are film-coated.
- Suitable film-coatings are known to those of skill in the art.
- the film-coating can be selected from among suitable polymers such as hydroxypropylmethylcellulose, ethyl cellulose, polyvinyl alcohol, and combinations thereof.
- Such coatings may also contain placticizers and other desirable components.
- the coatings are inert.
- Other suitable film-coatings can be readily selected by one of skill in the art.
- the weight percent of the film coat is generally in the range of 1 % w/w to 6 % w/w, about 2 % w/w, about 3% w/w, about 4% w/w or about 5%o w/w, and more desirably, about 2% w/w, based on the total weight of the coated composition.
- the invention further provides a method of delivering CCI-779 to a patient, said method comprising the step of administering a micronized CCI-779 dosing unit according to the invention. It is contemplated that when the formulations of this invention are used as an immunosuppressive or anti-inflammatory agent, they can be administered in conjunction with one or more other immunoregulatory agents.
- Such other antirejection chemotherapeutic agents include, but are not limited to azathioprine, corticosteroids, such as prednisone and methylprednisolone, cyclophosphamide, cyclosporin A, FK-506, OKT- 3, and ATG.
- Daily oral dosages of micronized CCI-779 can be 0.05 to 30 mg, about 1 mg to 25 mg, about 5 mg to about 10 mg. In one example, when micronized CCI-779 is used in combination therapy at daily doses in the range of 0.5 to 10 mg. In another example, micronized CCI-779 is used in monotherapy at daily doses in the range of 1 mg to 30 mg. In other embodiments, daily doses are 2 to 5 mg when micronized CCI-779 is used in combination therapy, and 5 to 1 mg when micronized CCI-779 is used as monotherapy. Treatment can be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect under the circumstances is reached.
- Precise dosages will be determined by the administering physician based on experience with the individual subject treated.
- the formulations of this invention are most desirably administered at a concentration that will generally afford effective results without causing any unacceptable harmful or deleterious side effects.
- the following provide representative examples of the formulations of this invention. These examples are illustrative only, and do not limit the invention.
- EXAMPLE 1 Directly Compressible Tablet Formulations Prepared By Employing Non- Micronized CCI-779
- the compositions included in this example employed non-micronized CCI-779 and were prepared with or without a surfactant.
- the tabletting was carried out by dry blending and direct compression method.
- CCI-779 tablets prepared by direct compression of nonmicronized CCI-779 with standard excipients and fillers, in the presence or absence of surfactants yielded tablets that did not exhibit rapid and complete drug release, and thereby resulted in an unsuitable formulation for CCI-779.
- EXAMPLE 2 Directly Compressible Tablet Formulations Prepared By Employing Micronized CCI-779, Sodium Lauryl Sulphate And Povidone The tablet formulations for this example are manufactured using the following protocol. Microcrystalline cellulose (Avicel PH-112) and povidone K-25 are passed through a screen and transferred to a V-blender of suitable size.
- Micronized CCI-779 is preblended with a portion of lactose anhydrous separately, then passed through a screen and added to the V-blender.
- Sodium lauryl sulfate, croscarmellose sodium, silicone dioxide and a portion of lactose anliydrous are passed through a screen and transferred to the V blender.
- the remaining lactose anhydrous is passed through a screen and transferred it to V-blender and the lids are closed. The material is blended without activation of intensifier bar.
- Magnesium stearate is passed through a screen, premixed with a weight equivalent portion of powder, blended from V-blender, transferred to the lubricant premix to V-blender and blended without activation of intensifier bar.
- the final blend is compressed using a tablet press with suitable tooling.
- Micronized CCI-779 And Poloxamer As Surfactant The table formulations for this example are manufactured according to the following protocol. Pass the poloxamer 188, microcrystalline cellulose (Avicel PH-112) and a portion of anliydrous lactose through a screen and blend. Mill the blend containing poloxamer with the help of a Fitz mill and transfer it to a V-blender of suitable size. Preblend a portion of anhydrous lactose with micronized butylated hydroxyanisole, butylated hydroxytoluene, EDTA calcium disodium, hydrous, and citric acid anliydrous. Then add CCI-779 to this preblend, mix and add to the V-blender.
- EXAMPLE 4 Dissolution of CCI-779 Tablets All the CCI-779 tablet formulations were evaluated by dissolution test. Dissolution test was performed using USP method II in 500 ml of 0.4%) sodium lauryl sulfate at 75 RPM paddle speed. Table 6 summarizes the dissolution characteristics of the neat CCI-779 API and various tablet formulations of CCI-779.
- EXAMPLE 5 Bioavailability of CCI-779 in Human - Evaluation of Oral Dosage Forms
- the three prototype tablet formulations containing micronized CCI-779 were further evaluated for absorption in human volunteers.
- a previously used clinical formulation prepared by wet granulation process was used as a control. The results of this biostudy are shown in Table 7 below.
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK04814371T DK1701698T3 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition for oral administration of CCI-779 |
SI200430611T SI1701698T1 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition for the oral admimistration of cci-779 |
JP2006549291A JP2007517879A (en) | 2004-01-08 | 2004-12-14 | Direct compressible pharmaceutical composition for oral administration of CCI-779 |
AU2004314213A AU2004314213A1 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition for the oral admimistration of CCI-779 |
CA002552595A CA2552595A1 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition for the oral admimistration of cci-779 |
DE602004011398T DE602004011398T2 (en) | 2004-01-08 | 2004-12-14 | DIRECT COMPRESSIBLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF CCI-779 |
PL04814371T PL1701698T3 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition for the oral admimistration of cci-779 |
EP04814371A EP1701698B1 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition for the oral admimistration of cci-779 |
BRPI0418373-8A BRPI0418373A (en) | 2004-01-08 | 2004-12-14 | pharmaceutical composition, oral cci-779 dosage unit, method of delivering a cci-779 to a patient, and use of micronized cci-779 |
MXPA06007829A MXPA06007829A (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition for the oral admimistration of cci-779. |
NO20062930A NO20062930L (en) | 2004-01-08 | 2006-06-22 | Directly compressible pharmaceutical composition for oral administration of CC-779 |
IL176519A IL176519A0 (en) | 2004-01-08 | 2006-06-22 | Directly compressible pharmaceutical composition for the oral administration of cci-779 |
HK06112221A HK1090308A1 (en) | 2004-01-08 | 2006-11-07 | Directly compressible pharmaceutical composition for the oral admnistration of cci-779 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53495104P | 2004-01-08 | 2004-01-08 | |
US60/534,951 | 2004-01-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005070393A2 true WO2005070393A2 (en) | 2005-08-04 |
WO2005070393A3 WO2005070393A3 (en) | 2006-09-28 |
Family
ID=34806893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/042178 WO2005070393A2 (en) | 2004-01-08 | 2004-12-14 | Directly compressible pharmaceutical composition of the rapamycin ester cci-779 |
Country Status (31)
Country | Link |
---|---|
US (1) | US20050152983A1 (en) |
EP (1) | EP1701698B1 (en) |
JP (1) | JP2007517879A (en) |
KR (1) | KR20060130162A (en) |
CN (1) | CN1921861A (en) |
AR (1) | AR047180A1 (en) |
AT (1) | ATE383859T1 (en) |
AU (1) | AU2004314213A1 (en) |
BR (1) | BRPI0418373A (en) |
CA (1) | CA2552595A1 (en) |
CR (1) | CR8491A (en) |
CY (1) | CY1107373T1 (en) |
DE (1) | DE602004011398T2 (en) |
DK (1) | DK1701698T3 (en) |
EC (1) | ECSP066757A (en) |
ES (1) | ES2298861T3 (en) |
GT (1) | GT200500003A (en) |
HK (1) | HK1090308A1 (en) |
HN (1) | HN2005000005A (en) |
IL (1) | IL176519A0 (en) |
MX (1) | MXPA06007829A (en) |
NO (1) | NO20062930L (en) |
PA (1) | PA8621201A1 (en) |
PE (1) | PE20050683A1 (en) |
PL (1) | PL1701698T3 (en) |
PT (1) | PT1701698E (en) |
RU (1) | RU2006122517A (en) |
TW (1) | TW200526213A (en) |
UA (1) | UA84903C2 (en) |
WO (1) | WO2005070393A2 (en) |
ZA (1) | ZA200605631B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006089312A2 (en) * | 2005-02-15 | 2006-08-24 | Wyeth | Orally bioavailable cci-779 tablet formulations |
US7446111B2 (en) | 2003-09-03 | 2008-11-04 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions |
JP2009542711A (en) * | 2006-06-28 | 2009-12-03 | エミスフェアー・テクノロジーズ・インク | Gallium nitrate preparation |
EP2662082A1 (en) | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1737869A1 (en) * | 2004-04-14 | 2007-01-03 | Wyeth a Corporation of the State of Delaware | Regiospecific synthesis of rapamycin 42-ester derivatives |
CN1946852A (en) * | 2004-04-27 | 2007-04-11 | 惠氏公司 | Labeling of rapamycin using rapamycin-specific methylases |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
AU2011260016B2 (en) | 2010-06-02 | 2013-08-22 | Fresenius Kabi Oncology Ltd. | Stable pharmaceutical compositions of Rapamycin esters |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
MA37711A1 (en) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Crystalline forms of a crude tyrosine kinase inhibitor |
BR112015001690A2 (en) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutations associated with resistance to bruton tyrosine kinase inhibitors (btk) |
CN104721158B (en) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | A kind of everolimus tablet of stabilization |
BR122023020985A2 (en) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | SOLID TABLET FORMULATION OF A BRUTON'S TYROSINE KINASE INHIBITOR |
JP6793652B2 (en) * | 2015-09-03 | 2020-12-02 | 日本化薬株式会社 | Pharmaceutical composition containing rapamycin or a derivative thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US20020091137A1 (en) * | 2000-11-15 | 2002-07-11 | American Home Products Corporation | Use of CCI-779 as an antineoplastic agent |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
JP2642486B2 (en) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | Ultrafine particle method for poorly soluble drugs |
US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5928668A (en) * | 1993-12-21 | 1999-07-27 | Applied Analytical Industries, Inc. | Method for dry blend compression of medicaments |
BE1009856A5 (en) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Pharmaceutical composition in the form of a solid release including macrolide and a vehicle. |
RU2186562C2 (en) * | 1996-08-22 | 2002-08-10 | Ресеч Трайангл Фармасьютикалс Лтд. | Composites presenting water-insoluble substance microparticles and method of their producing |
US5989591A (en) * | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
MXPA05002828A (en) * | 2002-09-17 | 2005-05-27 | Wyeth Corp | Oral formulations. |
UA83484C2 (en) * | 2003-03-05 | 2008-07-25 | Уайт | Method for treating breast cancer using combination of rapamycin derivative and aromatase inhibitor, pharmaceutical composition |
KR20060052880A (en) * | 2003-07-25 | 2006-05-19 | 와이어쓰 | Cci-779 lyophilized formulations |
KR20060057605A (en) * | 2003-08-07 | 2006-05-26 | 와이어쓰 | Regioselective synthesis of cci-779 |
RU2345999C2 (en) * | 2003-09-03 | 2009-02-10 | Уайт | Amorphous 42-ester of rapamycin and 3-hydroxy-2(hydroxymethyl)-2-methylpropanoic acid and pharmaceutical compositions containg it |
US20060142422A1 (en) * | 2004-12-07 | 2006-06-29 | Toshikazu Kobayashi | Hydrolysis resistant polyester compositions and articles made therefrom |
BRPI0607198A2 (en) * | 2005-02-15 | 2016-11-01 | Wyeth Corp | composition, use of composition diseases treatment method, and pharmaceutical packaging |
-
2004
- 2004-12-14 DK DK04814371T patent/DK1701698T3/en active
- 2004-12-14 PT PT04814371T patent/PT1701698E/en unknown
- 2004-12-14 CA CA002552595A patent/CA2552595A1/en not_active Abandoned
- 2004-12-14 UA UAA200608870A patent/UA84903C2/en unknown
- 2004-12-14 PL PL04814371T patent/PL1701698T3/en unknown
- 2004-12-14 ES ES04814371T patent/ES2298861T3/en active Active
- 2004-12-14 AT AT04814371T patent/ATE383859T1/en not_active IP Right Cessation
- 2004-12-14 WO PCT/US2004/042178 patent/WO2005070393A2/en active IP Right Grant
- 2004-12-14 CN CNA2004800399872A patent/CN1921861A/en active Pending
- 2004-12-14 KR KR1020067015655A patent/KR20060130162A/en not_active Application Discontinuation
- 2004-12-14 JP JP2006549291A patent/JP2007517879A/en not_active Withdrawn
- 2004-12-14 RU RU2006122517/15A patent/RU2006122517A/en not_active Application Discontinuation
- 2004-12-14 BR BRPI0418373-8A patent/BRPI0418373A/en not_active IP Right Cessation
- 2004-12-14 AU AU2004314213A patent/AU2004314213A1/en not_active Abandoned
- 2004-12-14 EP EP04814371A patent/EP1701698B1/en active Active
- 2004-12-14 DE DE602004011398T patent/DE602004011398T2/en active Active
- 2004-12-14 MX MXPA06007829A patent/MXPA06007829A/en active IP Right Grant
- 2004-12-27 TW TW093140750A patent/TW200526213A/en unknown
-
2005
- 2005-01-04 AR ARP050100016A patent/AR047180A1/en not_active Application Discontinuation
- 2005-01-05 GT GT200500003A patent/GT200500003A/en unknown
- 2005-01-06 HN HN2005000005A patent/HN2005000005A/en unknown
- 2005-01-06 US US11/030,685 patent/US20050152983A1/en not_active Abandoned
- 2005-01-06 PE PE2005000043A patent/PE20050683A1/en not_active Application Discontinuation
- 2005-01-07 PA PA20058621201A patent/PA8621201A1/en unknown
-
2006
- 2006-06-22 NO NO20062930A patent/NO20062930L/en not_active Application Discontinuation
- 2006-06-22 IL IL176519A patent/IL176519A0/en unknown
- 2006-06-28 CR CR8491A patent/CR8491A/en not_active Application Discontinuation
- 2006-07-07 ZA ZA200605631A patent/ZA200605631B/en unknown
- 2006-08-08 EC EC2006006757A patent/ECSP066757A/en unknown
- 2006-11-07 HK HK06112221A patent/HK1090308A1/en not_active IP Right Cessation
-
2008
- 2008-03-31 CY CY20081100359T patent/CY1107373T1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US20020091137A1 (en) * | 2000-11-15 | 2002-07-11 | American Home Products Corporation | Use of CCI-779 as an antineoplastic agent |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7446111B2 (en) | 2003-09-03 | 2008-11-04 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions |
WO2006089312A2 (en) * | 2005-02-15 | 2006-08-24 | Wyeth | Orally bioavailable cci-779 tablet formulations |
WO2006089312A3 (en) * | 2005-02-15 | 2006-10-19 | Wyeth Corp | Orally bioavailable cci-779 tablet formulations |
EP2662082A1 (en) | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
JP2009542711A (en) * | 2006-06-28 | 2009-12-03 | エミスフェアー・テクノロジーズ・インク | Gallium nitrate preparation |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
WO2017129772A1 (en) | 2016-01-29 | 2017-08-03 | Xellia Phamaceuticals Aps | Stable pharmaceutical compositions of temsirolimus |
Also Published As
Publication number | Publication date |
---|---|
CR8491A (en) | 2008-08-21 |
WO2005070393A3 (en) | 2006-09-28 |
PL1701698T3 (en) | 2008-03-31 |
ZA200605631B (en) | 2010-01-27 |
ATE383859T1 (en) | 2008-02-15 |
CN1921861A (en) | 2007-02-28 |
HK1090308A1 (en) | 2006-12-22 |
KR20060130162A (en) | 2006-12-18 |
PT1701698E (en) | 2008-03-27 |
CA2552595A1 (en) | 2005-08-04 |
ECSP066757A (en) | 2006-11-16 |
PA8621201A1 (en) | 2005-12-23 |
DE602004011398D1 (en) | 2008-03-06 |
EP1701698A2 (en) | 2006-09-20 |
CY1107373T1 (en) | 2012-12-19 |
ES2298861T3 (en) | 2008-05-16 |
AR047180A1 (en) | 2006-01-11 |
UA84903C2 (en) | 2008-12-10 |
DE602004011398T2 (en) | 2009-01-15 |
BRPI0418373A (en) | 2007-05-22 |
NO20062930L (en) | 2006-10-02 |
GT200500003A (en) | 2005-08-18 |
US20050152983A1 (en) | 2005-07-14 |
RU2006122517A (en) | 2008-02-20 |
JP2007517879A (en) | 2007-07-05 |
EP1701698B1 (en) | 2008-01-16 |
AU2004314213A1 (en) | 2005-08-04 |
TW200526213A (en) | 2005-08-16 |
IL176519A0 (en) | 2006-10-05 |
DK1701698T3 (en) | 2008-05-05 |
PE20050683A1 (en) | 2005-11-04 |
MXPA06007829A (en) | 2006-09-01 |
HN2005000005A (en) | 2009-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050152983A1 (en) | Directly compressible pharmaceutical composition for the oral administration of CCI-779 | |
US20060183766A1 (en) | Orally bioavailable CCI-779 formulations | |
CN102946869B (en) | The quick releasing formulation of gamma-hydroxybutyric acid and dosage form | |
JP6216325B2 (en) | Pharmaceutical formulation | |
EP1635830A2 (en) | Granulate formulation of the rapamycin ester cci-779 | |
US20090011013A1 (en) | Tacrolimus Combination Products | |
US8496967B2 (en) | Oral formulations | |
US11878078B2 (en) | Instant release pharmaceutical preparation of anticoagulant and preparation method therefor | |
CN111683659B (en) | Composition of amino pyran derivative | |
CN104363898A (en) | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate | |
AU2013203956A1 (en) | Oral formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004814371 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 176519 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1783/KOLNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2006-008491 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004314213 Country of ref document: AU Ref document number: 548274 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2552595 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12006501309 Country of ref document: PH Ref document number: 200480039987.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200605631 Country of ref document: ZA Ref document number: 2006549291 Country of ref document: JP Ref document number: PA/a/2006/007829 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2004314213 Country of ref document: AU Date of ref document: 20041214 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004314213 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 06075262 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067015655 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200601296 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006122517 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004814371 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067015655 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0418373 Country of ref document: BR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004814371 Country of ref document: EP |